Myomo at H.C. Wainwright conference: referral shift drives growth

Myomo reiterated 2026 revenue guidance of $45 million to $47 million and expects annual cash burn to decline 61% to about $7 million from $18 million in 2025. Q2 gross margin expanded 940bps year over year to 72%, supported by a 2% CMS price increase, cost reductions and 19% volume growth, while the company targets free-cash-flow breakeven at roughly $15 million of quarterly revenue. Growth is increasingly driven by Medicare-enabled referrals, with recurring sources now exceeding 50% of revenue and delivering approximately 10x the conversion rate of direct-to-consumer marketing, though sustained profitability and broader payer coverage remain key execution risks.

Analysis

MYO’s investable inflection is not the product pipeline but the quality of demand acquisition. A referral-led model should lower customer-acquisition cost, reduce authorization fallout, and smooth quarterly bookings; however, the economics will only be credible if revenue per active referral site rises alongside site count. The key near-term risk is that converting marketing savings into field-clinical hiring simply substitutes one fixed-cost sales channel for another before referral density reaches scale.

The margin story is less durable than the headline expansion suggests: part of the improvement derives from reimbursement pricing and one-time cost actions, while further gains require utilization growth against a relatively fixed clinical and manufacturing base. With cash modest relative to remaining burn, a shortfall versus the implied quarterly breakeven run-rate would revive dilution risk quickly. Management’s 2027 product, international, and coverage opportunities should receive limited current valuation credit until validation, manufacturing readiness, and payer adoption are independently demonstrated.

OBCK is a potentially meaningful channel partner rather than a clean public read-through: a successful rollout could establish O&P clinics as MYO’s lowest-cost distribution route, but it also shifts reimbursement exposure and customer ownership to the intermediary. ELV is only marginally exposed; its relevance is whether commercial payer contracts translate into faster authorizations, not material earnings contribution. Consensus may be underestimating the strategic value of earlier-stage patient access, but overestimating the speed at which a fragmented provider network becomes a repeatable, high-throughput channel.

Key Decisions for Investors

• Maintain MYO as a watch-list long rather than initiate aggressively before the next earnings release. Upgrade only if quarterly revenue is approaching the implied ~$15M breakeven level while operating cash use remains contained; this is the cleanest proof that referral conversion is producing operating leverage.
• For high-risk small-cap healthcare capital, consider a starter MYO position only after confirmation that referral-sourced revenue and repeat-site referrals continue to expand, with a 6-12 month horizon. Size for dilution risk; exit on a material cash-burn reacceleration, reduced revenue outlook, or evidence that field hiring raises opex faster than acquisition costs fall.
• Do not use ELV as a directional expression of the thesis. Monitor ELV-related in-network authorization data as a payer-adoption indicator; it is not sufficiently material to alter ELV earnings expectations.
• Set 2027 catalyst alerts for MyoPro 3.0 clinical validation, German hand-device launch readiness, and trial publication. Treat any delay, manufacturing redesign, or adverse reimbursement signal as thesis-falsifying because these longer-dated programs underpin much of the optionality beyond the core referral model.